Flibanserin , 10mMinDMSO , 167933-07-5

Synonym(s):
1,3-Dihydro-1-[2-[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]ethyl]-2H-benzimidazol-2-one;BIMT 17;BIMT 17BS

CAS NO.：167933-07-5

Empirical Formula: C20H21F3N4O

Molecular Weight: 390.4

MDL number: MFCD00918402

EINECS: 643-002-2

PRODUCT Properties

• Density: 1.292±0.06 g/cm3(Predicted)
• storage temp.: 2-8°C
• solubility: DMSO: soluble10mg/mL, clear
• form: powder
• pka: 12.12±0.30(Predicted)
• color: white to beige
• InChI: InChI=1S/C20H21F3N4O/c21-20(22,23)15-4-3-5-16(14-15)26-11-8-25(9-12-26)10-13-27-18-7-2-1-6-17(18)24-19(27)28/h1-7,14H,8-13H2,(H,24,28)
• InChIKey: PPRRDFIXUUSXRA-UHFFFAOYSA-N
• SMILES: C1(=O)N(CCN2CCN(C3=CC=CC(C(F)(F)F)=C3)CC2)C2=CC=CC=C2N1

Description and Uses

Flibanserin is a drug originally developed by Boehringer-Ingelheim and later Sprout Pharmaceuticals, which was approved in 2015 by the FDA for the treatment of premenopausal women with hypoactive sexual desire disorder (HSDD). The drug, which was originally developed for the treatment of depression by Boehringer- Ingelheim, is a full agonist of the 5-HT1A receptor, an antagonist of the 5-HT2A receptor, and a partial agonist of the dopamine-4 (D4) receptor, which triggers increased dopamine and norepinephrine levels along with decreased serotonin levels. In three randomized trials involving 2400 premenopausal women, the drug was found to increase the number of satisfying sexual events by 0.5-1.0 events per month and increased sexual desire on average by 10-12% over placebo. Side effects include decreased blood pressure and loss of consciousness, especially in subjects who consumed alcohol.

Antidepressant (5-HT1a agonist and 5-HT2 antagonist).

Safety

• Symbol(GHS): GHS06
• Signal word: Danger
• Hazard statements: H301-H315-H319-H335
• Precautionary statements: P301+P310+P330-P302+P352-P305+P351+P338
• Hazard Codes: T
• Risk Statements: 25-36/37/38
• Safety Statements: 26-45
• RIDADR: UN 2811 6.1 / PGIII
• WGK Germany: 3